Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Evotec : and Almirall enter into research collaboration in the field of dermatological diseases

share with twitter share with LinkedIn share with facebook
share via e-mail
09/19/2018 | 03:30pm CEST

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Almirall, S.A. (Spanish Stock Exchange.

Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive discovery, pre-clinical, clinical and sales milestone payments as well as tiered royalties.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: 'Evotec is pleased to partner with Almirall in the field of dermatology, who is a globally recognised leader in the field. The goal is to jointly address highly validated targets via a new approach that has the potential to deliver superior first-in-class drug products. This platform enables disruption of cell signalling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities.'

Dr Bhushan Hardas, Executive Vice President R&D, Chief Scientific Officer of Almirall, said: 'Our R&D strategy focuses towards achieving innovative and breakthrough products to cover patients' unmet needs. This partnership with Evotec, an expert in delivering fast growing and profitable drug discovery and development business, represents a step forward in offering outstanding solutions for the treatment of dermatology diseases with the best technology available and with substantial benefit to patients suffering from dermatological disorders.'


Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2017 was 755.8 million euros, and more than 1,830 employees are devoted to Science.


Tel.: (+34) 915 31 42 67


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.comand follow us on Twitter @EvotecAG.


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ALMIRALL SA -0.90% 17.53 End-of-day quote.109.94%
EVOTEC AG -1.16% 18.715 Delayed Quote.38.63%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EVOTEC AG
09/19EVOTEC : and Almirall enter into research collaboration in the field of dermatol..
09/17EVOTEC AG : Evotec And Almirall Enter Into Research Collaboration In The Field O..
09/17EVOTEC : And almirall enter into research collaboration in the field of dermatol..
09/13EVOTEC : And Celgene Enter Partnership In The Field Of Targeted Protein Degradat..
09/11EVOTEC : and Celgene enter partnership in the field of targeted protein degradat..
09/11EVOTEC AG : listed in MDAX
09/11EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
09/08EVOTEC : Evotech And Celgene Enter Partnership In The Field Of Targeted Protein ..
09/06EVOTEC : CENTOGENE and Evotec Sign Global Strategic Partnership on Drug Discover..
09/06EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
More news
News from SeekingAlpha
08/27CENTOGENE and Evotec sign global strategic partnership on drug discovery proj.. 
08/12Evotec AG 2018 Q2 - Results - Earnings Call Slides 
08/12Evotec AG (EVOTF) CEO Werner Lanthaler on Q2 2018 Results - Earnings Call Tra.. 
08/09Evotec AG reports Q2 results 
05/31Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research .. 
Financials (€)
Sales 2018 350 M
EBIT 2018 44,6 M
Net income 2018 34,2 M
Debt 2018 80,0 M
Yield 2018 -
P/E ratio 2018 78,90
P/E ratio 2019 57,82
EV / Sales 2018 8,21x
EV / Sales 2019 7,20x
Capitalization 2 795 M
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 23,2 €
Spread / Average Target 23%
EPS Revisions
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Eugenio Cosimino Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG38.63%3 293
CELLTRION, INC.--.--%33 313
LONZA GROUP21.04%24 749